Zobrazeno 1 - 10
of 44
pro vyhledávání: '"GEPNET"'
Autor:
Johan Spetz, Britta Langen, Nils-Petter Rudqvist, Toshima Z. Parris, Emman Shubbar, Johanna Dalmo, Bo Wängberg, Ola Nilsson, Khalil Helou, Eva Forssell-Aronsson
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-11 (2019)
Abstract Background 177Lu-octreotate is used for therapy of somatostatin receptor expressing neuroendocrine tumors with promising results, although complete tumor remission is rarely seen. Previous studies on nude mice bearing the human small intesti
Externí odkaz:
https://doaj.org/article/75cafa6b47d94faf94e9f39cd20a3b40
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Johan Spetz, Britta Langen, Nils Rudqvist, Toshima Z. Parris, Khalil Helou, Ola Nilsson, Eva Forssell-Aronsson
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background 177Lu-octreotate can be used to treat somatostatin receptor expressing neuroendocrine tumors. It is highly effective in animal models, but clinical studies have so far only demonstrated low cure rates. Hedgehog inhibitors have sho
Externí odkaz:
https://doaj.org/article/83f6168399ce465fa0dc065e378b9565
Autor:
Eva Forssell-Aronsson, Khalil Helou, Britta Langen, Nils Rudqvist, Johan Spetz, Ola Nilsson, Toshima Z. Parris
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Background 177Lu-octreotate can be used to treat somatostatin receptor expressing neuroendocrine tumors. It is highly effective in animal models, but clinical studies have so far only demonstrated low cure rates. Hedgehog inhibitors have shown therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3bd84d877c53cc4e763748ee61bb5d3
http://link.springer.com/article/10.1186/s12885-017-3524-x
http://link.springer.com/article/10.1186/s12885-017-3524-x
Autor:
Oktay E, Gd, Yalcin, Ekmekci S, Ds, Kahraman, Yalcin A, Degirmenci M, Dirican A, Altin Z, Ozdemir O, Zeki Gokhan Surmeli, Diniz G, Ayhan S, Bulut G, Erdogan A, Uslu R
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
EgeUn###
Purpose: Gastroenteropancreatic tumors (GEPNETs) is a heterogeneous disease with variable clinical course. While promising therapeutic options exist for other adult cancers, there are no new molecular-based treatments developed for GEPN
Purpose: Gastroenteropancreatic tumors (GEPNETs) is a heterogeneous disease with variable clinical course. While promising therapeutic options exist for other adult cancers, there are no new molecular-based treatments developed for GEPN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::94bf3f54bf1d9b060a4b6ad726929f16
https://hdl.handle.net/11454/15689
https://hdl.handle.net/11454/15689
Autor:
Oktay, Esin, Yalcin, Gizem Donmez, Ekmekci, Sumeyye, Kahraman, Dudu Solakoglu, Yalcin, Abdullah, Degirmenci, Mustafa, Dirican, Ahmet, zeynep altin, Ozdemir, Ozlem, Surmeli, Zeki, Diniz, Gulden, Ayhan, Semin, Bulut, Gulcan, Erdogan, Atike, Uslu, Ruchan
Publikováno v:
Web of Science
EgeUn###
Purpose: Gastroenteropancreatic tumors (GEPNETs) is a heterogeneous disease with variable clinical course. While promising therapeutic options exist for other adult cancers, there are no new molecular-based treatments developed for GEPN
Purpose: Gastroenteropancreatic tumors (GEPNETs) is a heterogeneous disease with variable clinical course. While promising therapeutic options exist for other adult cancers, there are no new molecular-based treatments developed for GEPN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ee21a650eb3a71f1ca65815a130094ee
https://hdl.handle.net/11454/29171
https://hdl.handle.net/11454/29171
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Johan, Spetz, Britta, Langen, Nils-Petter, Rudqvist, Toshima Z, Parris, Emman, Shubbar, Johanna, Dalmo, Bo, Wängberg, Ola, Nilsson, Khalil, Helou, Eva, Forssell-Aronsson
Publikováno v:
EJNMMI Research
Background 177Lu-octreotate is used for therapy of somatostatin receptor expressing neuroendocrine tumors with promising results, although complete tumor remission is rarely seen. Previous studies on nude mice bearing the human small intestine neuroe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f1fc02839d3f94b0a84129bfcde98f6
https://pubmed.ncbi.nlm.nih.gov/30895393
https://pubmed.ncbi.nlm.nih.gov/30895393
Autor:
Tobias, Hofving, Yvonne, Arvidsson, Bilal, Almobarak, Linda, Inge, Roswitha, Pfragner, Marta, Persson, Göran, Stenman, Erik, Kristiansson, Viktor, Johanson, Ola, Nilsson
Publikováno v:
Endocrine-Related Cancer
Experimental models of neuroendocrine tumour disease are scarce, and no comprehensive characterisation of existing gastroenteropancreatic neuroendocrine tumour (GEPNET) cell lines has been reported. In this study, we aimed to define the molecular cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680ac9bfd9602197a86b2bd1af6a9ffe
https://doi.org/10.1530/erc-17-0445e
https://doi.org/10.1530/erc-17-0445e
Autor:
Johan, Spetz, Britta, Langen, Nils, Rudqvist, Toshima Z, Parris, Khalil, Helou, Ola, Nilsson, Eva, Forssell-Aronsson
Publikováno v:
BMC Cancer
Background 177Lu-octreotate can be used to treat somatostatin receptor expressing neuroendocrine tumors. It is highly effective in animal models, but clinical studies have so far only demonstrated low cure rates. Hedgehog inhibitors have shown therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ebef1f6c0252b7f58d868a6cc41d68a0
https://pubmed.ncbi.nlm.nih.gov/28789624
https://pubmed.ncbi.nlm.nih.gov/28789624